WHO ICTRP trial
Clinical trial that compares MK-2870 with or without pembrolizumab to…
CTIS2023-504918-29-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-504918-29-00 |
|---|---|
| Public title | Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically removed. |
| Scientific title | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer - MK-2870-010 |
| Primary sponsor | Merck Sharp & Dohme LLC |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | Philippines;Turkey;Brazil;United Kingdom;Japan;China;Peru;South Africa;Mexico;Puerto Rico;Korea, Republic of;Singapore;Argentina;India;Costa Rica;Israel;United States;Canada;Taiwan;New… |
| Conditions | Hormone receptor positive breast cancer MedDRA version: 23.0Level: PTClassification code: 10083234Term: Hormone receptor positive breast cancer Class: 100000004864;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: -, Product Code:A02BA, Pharmaceutical Form: -, Other descriptive name: , Strength: , Product Name: , Product Code:SCP131876, Pharmaceutical Form: , Other descriptive name: , Strength: , Product Name: MK-2870, Product… |
| Registration date | Jan 30, 2024 |
| Target size | 1249 |
| Secondary IDs | U1111-1289-8119;165589 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: